Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMMBQ20)

Drug Name

CPI-818 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
T-cell lymphoma	2A90	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Patented Agent(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting T-cell-specific kinase (ITK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
JTE-051	DM2LBHN	Plaque psoriasis	EA90.0	Phase 2	[3]
Pyrazolo[4,3-c]pyridine derivative 2	DMCDFLQ	N. A.	N. A.	Patented	[4]
PMID27774824-Compound-Figure3Example7	DMXDOGK	N. A.	N. A.	Patented	[4]
BMS-509744	DMGH1LX	Inflammation	1A00-CA43.1	Investigative	[5]
BMS-488516	DM6Y1QF	Inflammation	1A00-CA43.1	Investigative	[5]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT03952078) A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of Corvus Pharmaceuticals.
3	Characterisation of a K390R ITK Kinase Dead Transgenic Mouse - Implications for ITK as a Therapeutic Target. PLoS One. 2014; 9(9): e107490.
4	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
5	Treatment of depersonalization with serotonin reuptake blockers. J Clin Psychopharmacol. 1990 Jun;10(3):200-3.